KERX Financial Facts

Total research and development: 7.62M
Total operating expenses: 30.22M
See Full Income Statement

Other liabilities: 1.29M
Property, plant and equipment, net: 5.01M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 8/5/16 *Est. EPS Growth Rate -39.3% *Last Qtr.
Average EPS % Beat Rate -21.8% Revenue Growth Rate +466.7% *Last Qtr.
Average % Move 1-Wk after EPS +2.3% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
4/28/16 Q116 -$0.39-$0.26 -$0.13$6.8M$6.63M N/A Details
2/25/16 Q415 -$0.36-$0.25 -$0.11$5.8M$5.68M N/A Details
8/5/15 Q215 -$0.26-$0.26 $0.00$2.5M$2.86M N/A Details
5/4/15 Q115 -$0.28-$0.30 +$0.02$1.2M$2.45M N/A Details
2/27/15 Q414 -$0.44-$0.37 -$0.07$569K$1.39M N/A Details
11/6/14 Q314 -$0.38-$0.27 -$0.11$256K$150K N/A Details
8/7/14 Q214 -$0.24-$0.25 +$0.01N/AN/A N/A Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details